Compare Abbott Laboratories (ABT) vs Booz Allen Hamilton Holding Corporation (BAH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Booz Allen Hamilton Holding Corporation — how do they compare? Abbott Laboratories trades at $109.36 (market cap $187.95B), while Booz Allen Hamilton Holding Corporation trades at $78.08 (market cap $9.37B). The key difference: Abbott Laboratories is far larger — about 20.1× Booz Allen Hamilton Holding Corporation's market cap, and Booz Allen Hamilton Holding Corporation pays the higher dividend (3.03%). Which is the better fit depends on your goals.
| ABT | BAH | |
|---|---|---|
Market Cap | $187.95B | $9.37B |
Sector | Health | Industrials |
52-Week High | $136.62 | $111.63 |
52-Week Low | $82.57 | $59.71 |
Enterprise Value | $214.96B | $12.99B |
Dividend Yield | 2.32% | 3.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
Booz Allen Hamilton (BAH) trades at $76.05, up 2.87% with a bullish technical signal and strong earnings beats. Recent quarters show consistent EPS outperformance, with Q2 2026 actual EPS of $1.81 beating the $1.49 estimate. The stock benefits from a discounted valuation with a P/E of 11.94 and robust cash flow growth, though revenue declined 4.2% year-over-year in Q1 2027. National security demand remains a key driver, offset by civil segment weakness.
Outlook is cautiously positive with a consensus price target of $84.67, implying 11% upside. Strengths include high ROE of 68.11% and margin expansion, but risks involve elevated debt levels and revenue volatility. Investors should weigh valuation appeal against execution risks in government contracting.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →
